title: Distinct and overlapping roles of interleukin-10 and CD25+ regulatory T cells in the inhibition of antitumor CD8 T-cell responses.
abstract: Lack of antitumor immunity is often related to impaired CD8 T-cell responses that could result from a poor priming capacity by tumor-infiltrating dendritic cells (TIDC) and/or further inhibition by regulatory T cells (T(reg)). Interleukin-10 (IL-10) has been implicated in the inhibition of TIDC as well as in the generation and functions of T(reg). Here, we address some of the respective and possibly overlapping roles of IL-10 and CD25+ T(reg) in CD8 antitumor immunity. Whereas tumor antigen-specific CD8 T cells proliferated in vivo in the presence of IL-10 or T(reg), optimal effector functions were observed in mice lacking both IL-10 and T(reg). Indeed, tumors grown in normal but not in IL-10-deficient or CD25-depleted mice induced tumor antigen-specific CD8 suppressor T cells. Suppression involved transforming growth factor-beta. Similarly, both IL-10 and T(reg) were responsible for impaired CD8 T cell priming by TIDCs, but IL-12 production by TIDCs was prevented only by T(reg)-independent IL-10. Subsequently, IL-10 defect and T(reg) depletion were required to achieve optimal induction of CD8 T-cell effectors by TIDC following CpG activation. Our results point out major redundant and nonredundant roles for IL-10 and T(reg) in the inhibition of TIDC-mediated generation of antitumor CD8 T-cell response.
authors.affiliation: Laboratory for Immunological Research, Schering-Plough Research Institute, Dardilly, France. dercamp@cervi-lyon.inserm.fr
authors.forename: Christophe
authors.initials: C
authors.lastname: Dercamp
authors.forename: Karine
authors.initials: K
authors.lastname: Chemin
authors.forename: Christophe
authors.initials: C
authors.lastname: Caux
authors.forename: Giorgio
authors.initials: G
authors.lastname: Trinchieri
authors.forename: Alain P
authors.initials: AP
authors.lastname: Vicari
mesh_terms: D000818:Animals; D000951:Antigens, Neoplasm / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology*; D002450:Cell Communication / Q000276:immunology; D018899:CpG Islands; D005260:Female; D016753:Interleukin-10 / Q000276:immunology*; D008213:Lymphocyte Activation / Q000276:immunology; D051379:Mice; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D010047:Ovalbumin / Q000096:biosynthesis / Q000235:genetics / Q000276:immunology; D015375:Receptors, Interleukin-2 / Q000096:biosynthesis / Q000172:deficiency / Q000276:immunology*; D050378:T-Lymphocytes, Regulatory / Q000276:immunology*; D013945:Thymoma / Q000235:genetics / Q000276:immunology; D014162:Transfection
chemical_list: D000951:Antigens, Neoplasm; D015375:Receptors, Interleukin-2; D016753:Interleukin-10; D010047:Ovalbumin